PUBLISHED FOR OPPOSITION
on 01 Oct 2024
Last Applicant/ Owned by
CH-3014 Bern
CH
Serial Number
79381493 filed on 01st Sep 2023
Registration Number
N/A
Correspondent Address
Scott D. Woldow
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
PLEQSTELB
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially Read More
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI; Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79381493
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 034845.394
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 01st Oct 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 01st Oct 2024 | PUBLISHED FOR OPPOSITION |
| 11th Sep 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 27th Aug 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 27th Aug 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 27th Aug 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 27th Aug 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 03rd Jun 2024 | REFUSAL PROCESSED BY IB |
| 16th May 2024 | REFUSAL PROCESSED BY MPU |
| 16th May 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |